Citation

Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, Huck BR, Johnson TL, Jones C, Jones RC, Mochalkin I, Morandi F, Nguyen N, Meyring M, Potnick JR, Santos DC, Schmidt R, Sherer B, Shutes A, Urbahns K, Follis AV, Wegener AA, Zimmerli SC, Liu-Bujalski L.: Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem, Volume 62 (17), 2019

Authors

Askew BC, Bender AT, Brugger N, Caldwell RD, Camps M, Dhanabal M, Dutt V, Eichhorn T, Follis AV, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, Huck BR, Johnson TL, Jones C, Jones RC, Liu-Bujalski L., Meyring M, Mochalkin I, Morandi F, Nguyen N, Potnick JR, Qiu H, Santos DC, Schmidt R, Sherer B, Shutes A, Urbahns K, Wegener AA, Zimmerli SC

Journal

J Med Chem

Year

2019

DOI

10.1021/acs.jmedchem.9b00794

PubMed

31368705

Machine-readable

REST APIRDF